- Home
- OCX
OCX
Oncocyte Corporation
as 06-02-2025 9:55am EST
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $5.42 | AVG Volume (30 days): | 40.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.92 - $4.75 | Next Earning Date: | 05-12-2025 |
| Revenue: | $3,843,000 | Revenue Growth: | 178.07% |
| Revenue Growth (this year): | -20.84% | Revenue Growth (next year): | 160.04% |
Latest Oncocyte Corporation News
OCX Breaking Stock News: Dive into OCX Ticker-Specific Updates for Smart Investing
GlobeNewswire
14 days ago
Medicare Boosts Reimbursement for Oncocyte’s Flagship Technology
GuruFocus.com
20 days ago
OncoCyte Corp (OCX) Q1 2025 Earnings Call Highlights: Strategic Advances in Transplant Testing ...
GlobeNewswire
21 days ago
Oncocyte Reports Q1 2025 Results and Business Progress
GlobeNewswire
a month ago
Oncocyte to Release First Quarter 2025 Results on May 12, 2025
GlobeNewswire
a month ago
Oncocyte Provides Positive Update on Clinical Trial Progress
GlobeNewswire
a month ago
Oncocyte’s Proprietary Assay Demonstrates Long-Term Clinical Validity
GlobeNewswire
2 months ago
Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
2 months ago
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts
Compare OCX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OCX Oncocyte Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.